PULMONARY FIBROSIS

This study tests an inhaled form of pirfenidone (AP01) in 375 adults with progressive pulmonary fibrosis (PPF), a condition where lung scarring worsens over time. Participants receive either a high dose, low dose, or placebo twice daily for 52 weeks, alongside their usual care. T…

This study is developing a new way to treat pulmonary fibrosis, a condition where the lungs become scarred and stiff. The approach uses tiny particles called liposomes, coated with hyaluronic acid, to deliver drugs directly to the cells that cause scarring. The research is being …

This study tests whether the drug sirolimus can prevent lung scarring (fibrosis) in people hospitalized with severe COVID-19 pneumonia. About 60 adults who need extra oxygen will receive sirolimus to see if it reduces the chance of long-term lung damage. The goal is to find a way…

This early-stage trial tests whether an inhaled protein from donated fat tissue can help people with pulmonary fibrosis, a lung-scarring disease. Seven participants will inhale the protein every 3 days for 7 doses. The study measures safety and changes in breathing and quality of…

This study is testing a new tool that uses chest CT scans to help doctors more accurately diagnose different types of pulmonary fibrosis, a lung scarring disease. Researchers will first create the tool by analyzing scans from 300 patients, then test it on 100 additional patients.…

This study collects and analyzes blood, DNA, and tissue samples from 315 adults with pulmonary fibrosis, their relatives, and healthy volunteers. The goal is to learn more about the disease's causes, not to test a new treatment. Researchers hope the findings will guide future the…

This study examines how well immunotherapy works for people with both lung cancer and pulmonary fibrosis (scarred lungs). Researchers will compare 200 patients with both conditions to similar patients without scarring, tracking survival and side effects. They also analyze tumor t…

This study looks at whether people with pulmonary fibrosis (a scarring lung disease) have shorter telomeres—the protective caps on the ends of chromosomes. Researchers will measure telomere length in blood samples from 100 Israeli patients and follow their health for two years. T…

This study follows 200 ICU patients with severe COVID-19 to see how often they develop lung scarring (pulmonary fibrosis). Researchers will use blood tests and CT scans to find early signs of scarring and identify risk factors. The goal is to understand how scarring affects recov…

This study follows 500 adults who had COVID-19 to see what health problems they face months later. Researchers will track symptoms like tiredness, breathing trouble, and lung damage. The goal is to learn how common these long-term issues are and who is most likely to have them.

This study follows 157 adults with pulmonary fibrosis who are taking nintedanib and enrolled in a patient support program in Spain. Researchers will measure how satisfied patients are with the program, their quality of life, and any depression symptoms over 12 months. The goal is…

This study looks at lung tissue from 80 people with pulmonary fibrosis to find unique genetic markers linked to scarring. By analyzing gene activity, researchers hope to better understand the disease and pave the way for new diagnostic tools and treatments. Participants must be 1…